CurrentKaiser PermanentePolicy N/A

Clinical Review Criteria — High‑Frequency Chest Wall Oscillation (HFCWO) Devices and Volara OLE System

Clinical review criteria governing medical necessity, coverage rationale, and documentation requirements for HFCWO airway clearance devices and the Volara oscillation & lung expansion system for Kaiser Permanente Washington members.

Policy Summary

PayerKaiser Permanente

PolicyClinical Review Criteria — HFCWO devices (ABI/Vest) and Volara OLE system

Policy CodePolicy N/A

Change TypeNo material changes noted in this revision

Effective DateN/A

Next Review DateN/A

Key ActionSubmit the last 6 months of clinical notes from the requesting provider or specialist to support medical necessity.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

SeveralDevices referenced

Insufficient/limitedEvidence conclusion

6‑month notesRequired doc

0Volara RCTs

E0469/A7021Coding update

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria — Non-Medicare Members

Covered when ONE of the following is met:

Cystic Fibrosis pathway: Member has diagnosis of cystic fibrosis AND is being managed by a pulmonologist AND has demonstrated compliance with chest physical therapy and flutter device at least twice daily (when age appropriate) AND HFCWO has been recommended by the pulmonologist.

From policy section for Non-Medicare Members

Coverage Criteria — Alternative pathway (Non-Medicare Members)

Covered when ALL of the following are met:

Alternative indications: 1) One of the following diagnoses: (i) Bronchiectasis evidenced by ALL of the following: a. Daily productive cough for at least 6 continuous months OR frequent (more than 2/year) exacerbations requiring antibiotic therapy; AND b. Confirmation by high-resolution, spiral, or standard CT scan; OR (ii) Neuromuscular disorder including any of: acid maltase deficiency; anterior horn cell diseases (including amyotrophic lateral sclerosis); hereditary muscular dystrophy; multiple sclerosis; myotonic disorders; other myopathies; paralysis of the diaphragm; post-polio; quadriplegia regardless of underlying etiology. 2) AND well-documented failure of standard treatments to adequately mobilize retained secretions, including: (a) chest physical therapy and flutter device at least twice daily (when age appropriate); (b) a pattern of hospitalizations at least annually or more; (c) significantly deteriorating clinical condition. 3) AND under the care of a pulmonologist. 4) AND had a rental trial to confirm compliance before purchase.

All listed conditions must be satisfied for authorization

Volara (OLE) system coverage stance

Informational / insufficient evidence

Volara System evidence summary: There is insufficient peer-reviewed published evidence to conclude safety and effectiveness of the Volara system for respiratory therapy. Literature searches identified no trials of Volara/Maximus and only small, high-risk-of-bias studies of predecessor devices (MetaNeb); additional randomized controlled trials are needed.

Hayes and ECRI evidence briefs and the document conclusion state insufficient evidence

Coverage summary

Coverage summarized from document statements and ECRI evidence review

Medicare & Non-Medicare covered when: HCPCS codes A7025, A7026, E0480, and E0483 are considered medically necessary when the member meets the clinical criteria in the applicable policy statements.

Document lists these HCPCS as covered when policy criteria are met

BiWaze Clear & Volara for Medicare: BiWaze Clear System and Volara System are considered medically necessary for Medicare members when criteria in the applicable policy statements are met.

Document distinguishes Medicare coverage for these systems

BiWaze Clear & Volara for Non-Medicare: For Non-Medicare members, BiWaze Clear System and Volara System are labeled Not Medically Necessary (experimental, investigational, or unproven).

Explicit non-coverage stance for Non-Medicare per document

Kaiser Permanente MTAC reviews over time concluded that available evidence for ThAIRapy/ABI Vest and other HFCWO systems is inadequate to demonstrate improved health outcomes for several indications. Multiple MTAC reviews found small, underpowered randomized trials, methodological limitations (selection bias, short follow-up, lack of washout, intermediate outcomes), and a lack of studies reporting clinical outcomes such as exacerbations or hospitalizations. As a result, the use of these HFCWO/vest devices for indications reviewed historically does not meet Kaiser Permanente Medical Technology Assessment criteria.

Requests for HFCWO therapy should meet the specific coverage criteria in this policy (diagnosis, documented failure of standard conservative airway-clearance measures, pulmonologist management, and other requirements). If those criteria are not satisfied, requests are at risk for denial because the MTAC evidence conclusions do not support routine coverage absent the listed clinical justifications.

For the BiWaze Clear System® and the Volara™ System the policy differentiates by payer: these systems are designated as Medicare: Considered Medically Necessary when criteria in the applicable policy statements are met, and Non‑Medicare: Not Medically Necessary — experimental, investigational or unproven. Providers should verify authorization requirements by plan type using the Pre-authorization Code Check and follow the same clinical criteria required for other HFCWO/airway-clearance devices for Medicare members.

The rationale for classifying HFCWO/vest devices as unsupported for coverage in many situations is rooted in repeated MTAC findings of insufficient empirical evidence: trials have been few, small, short in duration, often at risk of bias, and most did not assess meaningful clinical outcomes. Where evidence is limited or methodologically weak, the policy does not conclude safety and effectiveness and therefore requires adherence to the explicit coverage criteria before authorizing therapy.

Clinicians and requestors must submit documentation demonstrating that members satisfy the policy’s clinical pathways (for example, diagnosis confirmation, pulmonologist involvement, prior conservative therapy attempts) because the underlying evidence base alone does not substantiate broad routine coverage.

For the Volara/Maximus family, an ECRI/Hayes review found no identified studies evaluating the safety and effectiveness of the Volara or Maximus systems and only three small, high‑risk‑of‑bias studies of a predecessor (MetaNeb). Because those limited studies are insufficient to establish clinical benefit, the policy designates Volara as informational / insufficient evidence and supports a non‑medically necessary stance for Non‑Medicare members.

Consequently, non‑Medicare requests for Volara or related systems are labeled Not Medically Necessary — experimental, investigational or unproven in this document; Medicare requests may be considered only when the applicable policy criteria are explicitly met.

Prior Authorization, Documentation, and Denial Risk

Prior Authorization

Prior authorization requirements

Prior authorization is required and must document the diagnosis, that the member is being managed by a pulmonologist when specified, prior use and compliance with chest physical therapy and a flutter device at least twice daily (when age appropriate), failure of standard treatments, and a rental trial to confirm compliance before purchase when applicable.

Diagnosis documented (e.g., cystic fibrosis, bronchiectasis, or listed neuromuscular disorder)
Evidence of pulmonologist management where required
Documentation of prior chest physical therapy and flutter device use and compliance
Evidence of failure of standard treatments and rental trial before purchase (when applicable)

Billing Rule

Code-based prior authorization requirement

Certain HCPCS codes for HFCWO and related airway-clearance devices are considered medically necessary when the applicable policy criteria are met; the policy also adds BiWaze/Volara-specific codes (A7021, E0469) with distinct Medicare vs Non‑Medicare stances.

Covered when criteria met: A7025, A7026, E0480, E0483
BiWaze/Volara codes listed: A7021, E0469 (Non‑Medicare: Not Medically Necessary per document; Medicare: may be covered when criteria met)

Step Therapy

Step therapy / prior conservative treatments

Members must demonstrate prior compliance with chest physical therapy and a flutter device at least twice daily (when age appropriate) and have failed standard treatments to mobilize retained secretions before HFCWO is authorized; cystic fibrosis pathway requires pulmonologist management and pulmonologist recommendation.

Chest physical therapy and flutter device used at least twice daily (when age appropriate)
Well-documented failure of standard treatments to mobilize retained secretions
Pulmonologist management and recommendation for the cystic fibrosis pathway

Note

No step therapy specified

No mandated new step-therapy sequencing is specified for Volara implementation; the report notes no new infrastructure is needed though device-specific respiratory therapist training may be required.

No new infrastructure required
Respiratory therapists may need device-specific training

Documentation Required

Required documentation

Submit the last 6 months of clinical notes from the requesting provider and/or specialist to support medical necessity when requesting authorization.

Include progress notes, pulmonology notes, and documentation of prior airway-clearance therapies for the prior 6 months

Prior Authorization

Authorization verification

Use the Pre-authorization Code Check to verify authorization requirements for a specific code by plan type; coverage for codes depends on meeting the applicable policy statements.

Check plan-specific pre-authorization requirements before submission
Medicare and Non‑Medicare coverage for listed HCPCS codes is contingent on meeting policy criteria

Denial Risk

Denial risk for unmet clinical criteria

Requests that do not meet the listed clinical criteria — including required diagnosis, documented failure of standard therapies, pulmonologist management/recommendation, or rental-trial compliance where required — risk denial.

Missing documentation of pulmonologist management or recommendation for cystic fibrosis pathway
Insufficient evidence of prior chest physical therapy/flutter device use and compliance
No documentation of failure of standard treatments or rental trial when required

Denial Risk

Non-Medicare denial risk

For Non‑Medicare members, the BiWaze Clear System and Volara System are labeled Not Medically Necessary (experimental, investigational, or unproven) in this document and requests for those systems risk denial unless Medicare criteria distinctions apply.

BiWaze/Volara: Non‑Medicare status = Not Medically Necessary per policy
Medicare coverage may differ and is considered medically necessary when applicable policy criteria are met

Device Definitions

inv-22: High-Frequency Chest Wall Oscillation (HFCWO)

DefinitionAn external non-invasive therapy using an inflatable vest and air-pulse generator to oscillate the chest wall at high frequencies (typically 5–20 Hz) to mobilize airway secretions.

Typical treatmentTreatment sessions typically last 20–30 minutes with periods of compression separated by huff coughs.

Clinical uses discussedCommonly used in cystic fibrosis; studied for bronchiectasis and neuromuscular disorders.

Device componentsNon-stretching inflatable vest, large-bore tubing, and air-pulse generator creating controlled pressure pulses.

inv-23: Volara System (OLE)

DefinitionAn oscillating and lung expansion (OLE) device designed to provide oscillations, continuous positive expiratory pressure (CPEP/PEP), and aerosolized/nebulized medication delivery for mobilizing secretions and lung expansion in hospitalized and home patients.

Intended functionsMobilize secretions, provide lung expansion, prevent/treat atelectasis, and deliver medication and oxygen during CPEP and CHFO.

Evidence stanceECRI and other evidence reviews found insufficient peer‑reviewed literature to conclude safety and effectiveness; additional RCTs needed.

Predicate deviceAn early iteration, MetaNeb, served as the predicate device for FDA submission.

inv-24: Volara System — noncontinuous ventilation device purpose

Device classificationNoncontinuous ventilation device intended to mobilize lung secretions, provide lung expansion therapy, and treat/prevent atelectasis in hospitalized patients.

Clinical contextCompared with other hospital-based treatments for clearing secretions and reducing atelectasis; potential benefits noted but data are too few to conclude effectiveness.

Settings of useDesigned for hospitalized patients and available in a home care version (Volara Home Care System).

OpenPayer

Clinical Review Criteria — High‑Frequency Chest Wall Oscillation (HFCWO) Devices and Volara OLE System

Coverage and Medical Necessity Criteria

Billing Codes and Effective Dates

Prior Authorization, Documentation, and Denial Risk

Background and Rationale

Device Definitions

A7025	High frequency chest wall oscillation system vest, replacement for use with patient-owned equipment, each
A7026	High frequency chest wall oscillation system hose, replacement for use with patient-owned equipment, each
E0480	Percussor, electric or pneumatic, home model
E0483	High frequency chest wall oscillation system, includes all accessories and supplies, each

A7021	Supplies and accessories for lung expansion airway clearance, continuous high frequency oscillation, and nebulization device (e.g., handset, nebulizer kit, biofilter)
E0469	High frequency chest wall oscillation system vest, replacement for use with patient-owned equipment, each